Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma

BACKGROUND: The incidence of stage I and stage II lung adenocarcinoma (LUAD) is likely to increase with the introduction of annual screening programs for high-risk individuals. We aimed to identify a reliable prognostic signature with immune-related genes that can predict prognosis and help making i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Pancheng, Zheng, Yi, Wang, Yanyu, Wang, Yadong, Liang, Naixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542703/
https://www.ncbi.nlm.nih.gov/pubmed/33028329
http://dx.doi.org/10.1186/s12967-020-02545-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542703/
https://www.ncbi.nlm.nih.gov/pubmed/33028329
http://dx.doi.org/10.1186/s12967-020-02545-z

Ejemplares similares